The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
Open accessAbstract
Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit microsatellite instability (MSI), a molecular indicator of defective DNA mismatch repair (MMR), but the majority are microsatellite-stable (MSS). The high tumor mutational burden (TMB) and neoantigen load in MSI tumors favors the infiltration of immune effector cells, and antitumor immune responses within these tumors are strong relative to their MSS counterparts. MSI has emerged as a major predictive marker for the efficacy of immune checkpoint blockade over the last few years and nivolumab or pembrolizumab targeting PD-1 has been approved for patients with MSI refractory or metastatic CRC. However, some MSS tumors show DNA polymerase epsilon (POLE) mutations that also confer a very high TMB and may also be heavily infiltrated by immune cells making them amenable to respond to immune checkpoint inhibitors (ICI). In this review we discuss the role of the different immune landscapes in CRC and their relationships with defined CRC genetic subtypes. We discuss potential reasons why immune checkpoint blockade has met with limited success for the majority of CRC patients, despite the finding that immune cell infiltration of primary non-metastatic tumors is a strong predictive, and prognostic factor for relapse and survival. We then consider in which ways CRC cells develop mechanisms to resist ICI. Finally, we address the latest advances in CRC vaccination and how a personalized neoantigen vaccine strategy might overcome the resistance of MSI and MSS tumors in patients for whom immune checkpoint blockade is not a treatment option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Contrary to melanoma, a cancer with high number of mutations, glioblastoma is characterized by a low mutational load giving rise to far fewer neoantigens (80, 179).”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 21×
“Among the 4 CMS categories, CMS2 is the group with the fewest MSI tumors (only 1– 2%) (76).”
BackgroundMethodInfluentialThe immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,806
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · cited 2×
“Neoantigen-based vaccines showed promising results in terms of neoantigen-specific CD4 and CD8 T cell responses and survival in both melanoma (175, 176) and glioblastoma (177, 178), suggesting a potential benefit in other cancers including CRC.”
BackgroundMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · cited 3×
“A major genetic modification in CRC relies on the impairment of DNA mismatch repair (MMR) activity leading to a microsatellite instability (MSI) phenotype in 15% of tumors, different from the majority of microsatellite stable (MSS) tumors without such impairment which represent 85% of CRC cases (5).”
BackgroundProspective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“Indeed, stronger expression of genes coding for components of Th1 (TBX21, IRF1, and Interferon-γ) and CD8 T cell pathways (CD8α, granzyme B, granulysin) has been documented in CRC tumors without signs of early metastasis relative to tumors with such signs (10).”
BackgroundPatient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Organoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,360
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
CpG island methylator phenotype in cancer
Issa, J.-P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1507 · Cited by 1,098
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,056
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034 · cited 1×
“This discrepancy is not consistent with expectations from the Immunoscore which represents a strong predictor of clinical outcome at primary resection in CRC, irrespective of the microsatellite status (61, 101).”
ResultParkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7229 · Cited by 991
Sadanandam, A., Lyssiotis, C. A., Homicsko, K., Collisson, E. A., Gibb, W. J., Wullschleger, S., Ostos, L. C. G., Lannon, W. A., Grotzinger, C., Del Rio, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3175 · Cited by 960
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 954
γδ T cell effector functions: a blend of innate programming and acquired plasticity
Bonneville, M., O'Brien, R. L., & Born, W. K. (2010) · Nature Reviews Immunology · doi:10.1038/nri2781 · Cited by 952
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1154 · Cited by 937
The Chromosomal Instability Pathway in Colon Cancer
Pino, M. S., & Chung, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.065 · Cited by 932
Dendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2017) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 927
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 913
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D. J., van de Haar, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay2574 · Cited by 813
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Chauvin, J.-M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 784
De Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771
Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M. A., Vallejo, C., Martos, J. A., & Moreno, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970615)79:12<2320::aid-cncr5>3.0.co;2-p · Cited by 716
De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S., Stover, E., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 684
Genetic alterations in colorectal cancer.
Armaghany, T., Wilson, J. D., Chu, Q., & Mills, G. M. (2012) · Europe PMC (PubMed Central) · Cited by 673
Colorectal cancer development and advances in screening
Balchen, V., & Simon, K. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s109285 · Cited by 665
Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590
High Macrophage Infiltration along the Tumor Front Correlates with Improved Survival in Colon Cancer
Forssell, J., Öberg, A., Henriksson, M. L., Stenling, R., Jung, A., & Palmqvist, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2073 · Cited by 566
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., & Engleman, E. G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141226398 · Cited by 541
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1327 · Cited by 535
Angelova, M., Charoentong, P., Hackl, H., Fischer, M. L., Snajder, R., Krogsdam, A. M., Waldner, M. J., Bindea, G., Mlecnik, B., Galon, J., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0620-6 · Cited by 522
Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery
Weeber, F., Ooft, S. N., Dijkstra, K. K., & Voest, E. E. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.012 · Cited by 486
Weeber, F., van de Wetering, M., Hoogstraat, M., Dijkstra, K. K., Krijgsman, O., Kuilman, T., Gadellaa-van Hooijdonk, C. G. M., van der Velden, D. L., Peeper, D. S., Cuppen, E. P. J. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516689112 · Cited by 482
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
Edin, S., Wikberg, M. L., Dahlin, A. M., Rutegård, J., Öberg, Å., Oldenborg, P.-A., & Palmqvist, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047045 · Cited by 454
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Zhang, C., Wang, Z., Yang, Z., Wang, M., Li, S., Li, Y., Zhang, R., Xiong, Z., Wei, Z., Shen, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.010 · Cited by 451
Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
Tran Janco, J. M., Lamichhane, P., Karyampudi, L., & Knutson, K. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403134 · Cited by 440
Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer
Budinska, E., Popovici, V., Tejpar, S., D'Ario, G., Lapique, N., Sikora, K. O., Di Narzo, A. F., Yan, P., Hodgson, J. G., Weinrich, S., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4212 · Cited by 409
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J. M., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 380
Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer
Posch, F., Silina, K., Leibl, S., Mündlein, A., Moch, H., Siebenhüner, A., Samaras, P., Riedl, J., Stotz, M., Szkandera, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1378844 · Cited by 380
Liu, J., Duan, Y., Cheng, X., Chen, X., Xie, W., Long, H., Lin, Z., & Zhu, B. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.021 · Cited by 361
Roepman, P., Schlicker, A., Tabernero, J., Majewski, I., Tian, S., Moreno, V., Snel, M. H., Chresta, C. M., Rosenberg, R., Nitsche, U., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28387 · Cited by 346
Schütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., et al. (2017) · Nature Communications · doi:10.1038/ncomms14262 · Cited by 339
Datar, I., Sanmamed, M. F., Wang, J., Henick, B. S., Choi, J., Badri, T., Dong, W., Mani, N., Toki, M., Mejías, L. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4142 · Cited by 326
Domingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
[Genetic alterations in colorectal cancer].
Laurent‐Puig, P. (1994) · PubMed · Cited by 293
Herrera, M., Herrera, A., Domínguez, G., Silva, J., García, V., García, J. M., Gómez, I., Soldevilla, B., Muñoz, C., Provencio, M., et al. (2013) · Cancer Science · doi:10.1111/cas.12096 · Cited by 289
Zhang, B., Wang, Z., Wu, L., Zhang, M., Li, W., Ding, J., Zhu, J., Wei, H., & Zhao, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057114 · Cited by 269
Limagne, E., Euvrard, R., Thibaudin, M., Rébé, C., Derangère, V., Chevriaux, A., Boidot, R., Végran, F., Bonnefoy, N., Vincent, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3164 · Cited by 264
Kimura, T., McKolanis, J. R., Dzubinski, L. A., Islam, K., Potter, D. M., Salazar, A. M., Schoen, R. E., & Finn, O. J. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0275 · Cited by 263
Schlicker, A., Beran, G., Chresta, C. M., McWalter, G., Pritchard, A., Weston, S., Runswick, S., Davenport, S., Heathcote, K., Castro, D. A., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-66 · Cited by 256
Aleksic, M., Liddy, N., Molloy, P. E., Pumphrey, N., Vuidepot, A., Chang, K., & Jakobsen, B. K. (2012) · European Journal of Immunology · doi:10.1002/eji.201242606 · Cited by 248
Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Pasch, C. A., Favreau, P. F., Yueh, A. E., Babiarz, C. P., Gillette, A. A., Sharick, J. T., Karim, M. R., Nickel, K. P., DeZeeuw, A. K., Sprackling, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3590 · Cited by 234
Chen, Y.-P., Zhang, Y., Lv, J.-W., Li, Y.-Q., Wang, Y.-Q., He, Q.-M., Yang, X.-J., Sun, Y., Mao, Y.-P., Yun, J.-P., et al. (2017) · Theranostics · doi:10.7150/thno.21471 · Cited by 232
Waniczek, D., Lorenc, Z., Śnietura, M., Wesecki, M., Kopec, A., & Muc-Wierzgoń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0463-9 · Cited by 228
Viral vector-based therapeutic cancer vaccines
Larocca, C., & Schlom, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325e63 · Cited by 222
Villarroel-Espindola, F., Yu, X., Datar, I., Mani, N., Sanmamed, M., Velcheti, V., Syrigos, K., Toki, M., Zhao, H., Chen, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2542 · Cited by 215
Gong, J., Wang, C., Lee, P. P., Chu, P., & Fakih, M. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0016 · Cited by 207
Adoptive T-Cell Therapy for Cancer
Yang, J. C., & Rosenberg, S. A. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 206
Xiong, Y., Wang, K., Zhou, H., Peng, L., You, W., & Fu, Z. (2018) · Cancer Medicine · doi:10.1002/cam4.1745 · Cited by 195
Ling, K. L., Pratap, S., Bates, G. J., Singh, B., Mortensen, N. J. M., George, B. D., Warren, B. F., Piris, J., Roncador, G., Fox, S. B., et al. (2007) · PubMed · Cited by 191
Tosolini, M., Pont, F., Poupot, M., Vergez, F., Nicolau-Travers, M.-L., Vermijlen, D., Sarry, J. E., Dieli, F., & Fournié, J.-J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1284723 · Cited by 191
OuYang, L.-Y., Wu, X.-J., Ye, S.-B., Zhang, R.-X., Li, Z.-L., Liao, W., Pan, Z.-Z., Zheng, L.-M., Zhang, X.-S., Wang, Z., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0410-7 · Cited by 189
Self-citationTsuruma, T., Hata, F., Torigoe, T., Furuhata, T., Idenoue, S., Kurotaki, T., Yamamoto, M., Yagihashi, A., Ohmura, T., Yamaguchi, K., et al. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-19 · Cited by 181
Kloor, M., Becker, C., Benner, A., Woerner, S. M., Gebert, J., Ferrone, S., & von Knebel Doeberitz, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0044 · Cited by 178
Nair, S. K., Hull, S., Coleman, D., Gilboa, E., Lyerly, H. K., & Morse, M. A. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990702)82:1<121::aid-ijc20>3.0.co;2-x · Cited by 174
Sandel, M. H., Dadabayev, A. R., Menon, A. G., Morreau, H., Melief, C. J. M., Offringa, R., van der Burg, S. H., Janssen-van Rhijn, C. M., Ensink, N. G., Tollenaar, R. A. E. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1448 · Cited by 173
Peng, Y.-P., Zhu, Y., Zhang, J.-J., Xu, Z.-K., Qian, Z.-Y., Dai, C.-C., Jiang, K.-R., Wu, J.-L., Gao, W.-T., Li, Q., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-262 · Cited by 172
Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer
Meraviglia, S., Lo Presti, E., Tosolini, M., La Mendola, C., Orlando, V., Todaro, M., Catalano, V., Stassi, G., Cicero, G., Vieni, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1347742 · Cited by 172
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
Kang, C.-W., Dutta, A., Chang, L.-Y., Mahalingam, J., Lin, Y.-C., Chiang, J.-M., Hsu, C.-Y., Huang, C.-T., Su, W.-T., Chu, Y.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep15659 · Cited by 163
Santin, A. D., Bellone, S., Buza, N., Choi, J., Schwartz, P. E., Schlessinger, J., & Lifton, R. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1031 · Cited by 160
Vaccine adjuvants: smart components to boost the immune system
Bastola, R., Noh, G., Keum, T., Bashyal, S., Seo, J.-E., Choi, J., Oh, Y., Cho, Y., & Lee, S. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0969-z · Cited by 158
Immune evasion of microsatellite unstable colorectal cancers
Kloor, M., Michel, S., & Doeberitz, M. V. K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25283 · Cited by 156
Koelzer, V. H., Canonica, K., Dawson, H., Sokol, L., Karamitopoulou, E., Lugli, A., & Zlobec, I. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1106677 · Cited by 156
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
Nebot-Bral, L., Brandão, D., Verlingue, L., Rouleau, É., Caron, O., Despras, E., Dakdouki, Y. E., Champiat, S., Aoufouchi, S., Leary, A. F., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.026 · Cited by 151
Molecular phenotypes of colorectal cancer and potential clinical applications
Kocarnik, J., Shiovitz, S., & Phipps, A. I. (2015) · Gastroenterology report · doi:10.1093/gastro/gov046 · Cited by 145
Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients
Rocca, Y., Roberti, M. P., Arriaga, J. M., Amat, M., Bruno, L. I., Pampena, M. B., Huertas, E., Loria, F. S., Pairola, A., Bianchini, M., et al. (2012) · Innate Immunity · doi:10.1177/1753425912453187 · Cited by 144
Scurr, M. J., Ladell, K., Besneux, M., Christian, A. D., Hockey, T., Smart, K., Bridgeman, H. M., Hargest, R., Phillips, S. M., Davies, M. M., et al. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.62 · Cited by 142
Albacker, L. A., Wu, J., Smith, P. G., Warmuth, M., Stephens, P. J., Zhu, P., Yu, L., & Chmielecki, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176181 · Cited by 139
Sun, H.-L., Xin Min, Z. H. O. U., Xue, Y., Wang, K., Shen, Y., Mao, J., Guo, H., & Miao, Z. (2012) · Europe PMC (PubMed Central) · doi:10.3748/wjg.v18.i25.3303 · Cited by 138
Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity
Pawelec, G., Verschoor, C. P., & Ostrand‐Rosenberg, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01099 · Cited by 137
Self-citationThe present status and future prospects of peptide-based cancer vaccines
Hirayama, M., & Nishimura, Y. (2016) · International Immunology · doi:10.1093/intimm/dxw027 · Cited by 135
Characteristics and significance of colorectal cancer associated lymphoid reaction
Väyrynen, J. P., Väyrynen, S. A., Klintrup, K., Mäkelä, J. T., Herzig, K., Karttunen, T. J., Tuomisto, A., & Mäkinen, M. J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28533 · Cited by 133
Tumor-associated macrophages remodeling EMT and predicting survival in colorectal carcinoma
Li, S., Xu, F., Zhang, J., Wang, L., Zheng, Y., Wu, X., Wang, J., Huang, Q., & Lai, M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1380765 · Cited by 126
Interleukin-17: A Promoter in Colorectal Cancer Progression
Wu, D., Wu, P., Huang, Q., Liu, Y., Ye, J., & Huang, J. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/436307 · Cited by 124
Regulatory T‐cell heterogeneity and the cancer immune response
Ward‐Hartstonge, K. A., & Kemp, R. A. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.43 · Cited by 122 · cited 1×
“Tregs are involved inter alia in the suppression of inflammation mediated by effector T cells by several mechanisms including the release of TGF-β and IL10 (44).”
BackgroundTIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer
Fucikova, J. P., Raková, J., Hensler, M., Kašíková, L., Belicova, L., Hladíková, K., Truxová, I., Škapa, P., Laco, J., Pecen, L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4175 · Cited by 122
Complex pattern of immune evasion in MSI colorectal cancer
Özcan, M., Janikovits, J., Doeberitz, M. V. K., & Kloor, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445453 · Cited by 120
Lin, Y., Mahalingam, J., Chiang, J., Su, P., Chu, Y., Lai, H., Fang, J., Huang, C., Chiu, C., & Lin, C. (2012) · International Journal of Cancer · doi:10.1002/ijc.27784 · Cited by 118
Miyagi, Y., Imai, N., Sasatomi, T., Yamada, A., Mine, T., Katagiri, K., Nakagawa, M., Muto, A., Okouchi, S., Isomoto, H., et al. (2001) · PubMed · Cited by 115
Laheurte, C., Dosset, M., Vernerey, D., Boullerot, L., Gaugler, B., Gravelin, E., Kaulek, V., Jacquin, M., Cuche, L., Eberst, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0531-5 · Cited by 114
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
Xie, S., Huang, J., Qiao, Q., Zang, W., Hong, S., Tan, H., Dong, C., Yang, Z., & Ni, L. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2227-8 · Cited by 105
Role of dendritic cells in progression and clinical outcome of colon cancer
Gulubova, M. V., Ananiev, J. R., Vlaykova, T. I., Yovchev, Y., Tsoneva, V., & Manolova, I. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1334-1 · Cited by 103
Lesterhuis, W. J., de Vries, I. J. M., Schuurhuis, D. H., Boullart, A. C. I., Jacobs, J. F. M., de Boer, A. J., Scharenborg, N. M., Brouwer, H., van de Rakt, M. W. M. M., Figdor, C. G., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl072 · Cited by 101
Sinicrope, F. A., Shi, Q., Allegra, C. J., Smyrk, T. C., Thibodeau, S. N., Goldberg, R. M., Meyers, J. P., Pogue-Geile, K. L., Yothers, G., Sargent, D. J., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5469 · Cited by 99
Rocca, Y. S., Roberti, M. P., Juliá, E. P., Pampena, M. B., Bruno, L., Rivero, S., Huertas, E., Sánchez Loria, F., Pairola, A., Caignard, A., et al. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00413 · Cited by 97
The perfect personalized cancer therapy: cancer vaccines against neoantigens
Aurisicchio, L., Pallocca, M., Ciliberto, G., & Palombo, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0751-1 · Cited by 97
Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells
Dadabayev, A. R., Sandel, M. H., Menon, A. G., Morreau, H., Melief, C. J. M., Offringa, R., van der Burg, S. H., Rhijn, C. M. J., Ensink, N. G., Tollenaar, R. A. �. �., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0548-2 · Cited by 96
Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer
Gurjao, C., Liu, D., Hofree, M., AlDubayan, S. H., Wakiro, I., Su, M.-J., Felt, K. D., Gjini, E., Brais, L. K., Rotem, A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0683 · Cited by 94
Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection
Karanikas, V., Thynne, G., Mitchell, P., Ong, C.-S., Gunawardana, D. H., Blum, R., Pearson, J. M., Lodding, J., Pietersz, G. A., Broadbent, R., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200103000-00012 · Cited by 93
Sveen, A., Johannessen, B., Tengs, T., Danielsen, S. A., Eilertsen, I. A., Lind, G. E., Berg, K. C. G., Leithe, E., Meza‐Zepeda, L. A., Domingo, E., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0434-0 · Cited by 92
Timperi, E., Pacella, I., Schinzari, V., Focaccetti, C., Sacco, L., Farelli, F., Caronna, R., Bene, G. D., Longo, F., Ciardi, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1175800 · Cited by 86
Harding, J. J., Patnaik, A., Moreno, V., Stein, M. N., Jankowska, A. M., de Mendizábal, N. V., Liu, Z. T., Koneru, M., & Calvo, E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.12 · Cited by 86
Bourdais, R., Rousseau, B., Pujals, A., Boussion, H., Joly, C., Guillemin, A., Baumgaertner, I., Neuzillet, C., & Tournigand, C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.027 · Cited by 84
Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer
Xu, B., Yuan, L., Gao, Q., Yuan, P., Zhao, P., Yuan, H., Fan, H., Li, T., Qin, P., Han, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4112 · Cited by 83
Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer
Blessin, N. C., Simon, R., Kluth, M., Fischer, K., Hube‐Magg, C., Li, W., Makrypidi‐Fraune, G., Wellge, B., Mandelkow, T., Debatin, N. F., et al. (2019) · Disease Markers · doi:10.1155/2019/5160565 · Cited by 82
The emerging role of immunotherapy in colorectal cancer
Lynch, D. H., & Murphy, A. G. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.08.29 · Cited by 76
Tada, K., Kitano, S., Shoji, H., Nishimura, T., Shimada, Y., Nagashima, K., Aoki, K., Hiraoka, N., Honma, Y., Iwasa, S., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0298 · Cited by 74
Immunological landscape of consensus clusters in colorectal cancer
Karpiński, P., Rossowska, J., & Sasiadek, M. M. (2017) · Oncotarget · doi:10.18632/oncotarget.22169 · Cited by 74
Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer
Karlsson, M., Marits, P., Dahl, K., Dagöö, T., Enerbäck, S., Thörn, M., & Winqvist, O. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0920-8 · Cited by 73
Kobayashi, M., Chung, J., Beg, M. S., Arriaga, Y. E., Verma, U. N., Courtney, K. D., Mansour, J. C., Haley, B., Khan, S. A., Horiuchi, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0330 · Cited by 68
Michel, S., Linnebacher, M., Alcaniz, J., Voss, M., Wagner, R., Dippold, W. G., Becker, C., Doeberitz, M. V. K., Ferrone, S., & Kloor, M. (2009) · International Journal of Cancer · doi:10.1002/ijc.25106 · Cited by 65
Okuno, K., Sugiura, F., Hida, J., Tokoro, T., 石丸, 英., Sukegawa, Y., & Ueda, K. (2010) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2010.182 · Cited by 64
Wang, C., Gong, J., Tu, T. Y., Lee, P. P., & Fakih, M. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.09 · Cited by 63
Snook, A. E., Baybutt, T. R., Xiang, B., Abraham, T. S., Flickinger, J. C., Hyslop, T., Zhan, T., Kraft, W. K., Sato, T., & Waldman, S. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0576-2 · Cited by 62
POLE somatic mutations in advanced colorectal cancer
Guerra, J., Pinto, C., Pinto, D., Pinheiro, M., Silva, R., Peixoto, A., Rocha, P., Veiga, I., Santos, C., Santos, R. P., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1245 · Cited by 61
Zhen, Y.-H., Liu, X., Yang, Y., Li, B., Tang, J., Zeng, Q.-X., Hu, J., Zeng, X.-N., Zhang, L., Wang, Z., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1715-3 · Cited by 60
Janikovits, J., Müller, M., Krzykalla, J., Körner, S., Echterdiek, F., Lahrmann, B., Grabe, N., Schneider, M. A., Benner, A., Doeberitz, M. V. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1390640 · Cited by 60
Strasser, K., Birnleitner, H., Beer, A., Pils, D., Gerner, M. C., Schmetterer, K. G., Bachleitner‐Hofmann, T., Stift, A., Bergmann, M. M., & Oehler, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1537693 · Cited by 59
The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers
Liu, G., Liu, R., Yan, J.-P., An, X., Wu, J., Ling, Y., Chen, J.-W., Bei, J., Zuo, X.-Y., Cai, M.-Y., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy004 · Cited by 55
Yomoda, T., Sudo, T., Kawahara, A., Shigaki, T., Shimomura, S., Tajiri, K., Nagasu, S., Fujita, F., Kinugasa, T., & Akagi, Y. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-07110-z · Cited by 51
Okuno, K., Sugiura, F., Inoue, K., & Sukegawa, Y. (2014) · PubMed · Cited by 44
Stelloo, E., Versluis, M., Nijman, H. W., de Bruyn, M., Plat, A., Osse, E. M., van Dijk, R. H., Nout, R. A., Creutzberg, C. L., de Bock, G. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9414 · Cited by 43
Curigliano, G., Gelderblom, H. A. J., Mach, N., Doi, T., Tai, W. M. D., Forde, P. M., Sarantopoulos, J., Bedard, P. L., Lin, C., Hodi, S. F., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct183 · Cited by 41
Surmann, E.-M., Voigt, A. Y., Michel, S., Bauer, K. H., Reuschenbach, M., Ferrone, S., Doeberitz, M. V. K., & Kloor, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1638-4 · Cited by 40
Shimodaira, S., Sano, K., Hirabayashi, K., Koya, T., Higuchi, Y., Mizuno, Y., Yamaoka, N., Yuzawa, M., Kobayashi, T., Ito, K., et al. (2015) · Vaccines · doi:10.3390/vaccines3041004 · Cited by 39
The prognostic value of FOXP3+ T regulatory cells in colorectal cancer.
Vlad, C. I., Kubelac, P. M., Fetică, B., Vlad, D., Irimie, A., & Achimaș-Cădariu, P. (2015) · PubMed · Cited by 38
Papadopoulos, K. P., Lakhani, N. J., Johnson, M. L., Park, H., Wang, D., Yap, T. A., Dowlati, A., Maki, R. G., Lynce, F. C., Ulahannan, S. V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2508 · Cited by 38
Berry, J., Vreeland, T. J., Trappey, A. F., Hale, D. F., Peace, K. M., Tyler, J. A., Walker, A. S., Brown, R. A., Herbert, G. S., Yi, F., et al. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1226132 · Cited by 37
Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer
Aka, A. A., Rappaport, J. A., Pattison, A. M., Sato, T., Snook, A. E., & Waldman, S. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1292124 · Cited by 36
Laheurte, C., Galaine, J., Beziaud, L., Dosset, M., Kerzerho, J., Jacquemard, C., Gaugler, B., Ferrand, C., Dormoy, A., Aubin, F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1137416 · Cited by 33
Kim, K.-J., Yang, H. K., Kim, W. H., & Kang, G. H. (2017) · Oncotarget · doi:10.18632/oncotarget.19439 · Cited by 33
Dunne, M. R., Ryan, C., Nolan, B., Tosetto, M., Geraghty, R., Winter, D. C., O’Connell, P. R., Hyland, J. M., Doherty, G. A., Sheahan, K. D., et al. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00050 · Cited by 27
Scurr, M. J., Bloom, A. C., Pembroke, T., Srinivasan, R., Brown, C. M., Smart, K., Bridgeman, H. M., Davies, M., Hargest, R., Phillips, S. M., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0035 · Cited by 23
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Granier, C., Vinatier, E., Colin, E., Mandavit, M., Dariane, C., Verkarre, V., Biard, L., Zein, R. M. E., Lesaffre, C., Galy–Fauroux, I., et al. (2018) · Journal of Visualized Experiments · doi:10.3791/56606 · Cited by 19
Kawamura, J., Sugiura, F., Sukegawa, Y., Yoshioka, Y., Hida, J., Hazama, S., & Okuno, K. (2018) · Cancer Science · doi:10.1111/cas.13547 · Cited by 19
Ishii, H., Azuma, K., Kawahara, A., Matsuo, N., Tokito, T., Kinoshita, T., Yamada, K., Sasada, T., Akiba, J., & Hoshino, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18651 · Cited by 18
Besneux, M., Greenshields‐Watson, A., Scurr, M. J., MacLachlan, B. J., Christian, A. D., Davies, M. M., Hargest, R., Phillips, S. M., Godkin, A. J., & Gallimore, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2266-1 · Cited by 17
Kawamura, J., Sugiura, F., Sukegawa, Y., Yoshioka, Y., Hida, J., Hazama, S., & Okuno, K. (2018) · Oncology Letters · doi:10.3892/ol.2018.7905 · Cited by 14
Research works printed but not linked: 8
- Pryczynicz, 2016, Dysfunctions in the mature dendritic cells are associated with the presence of metastases of colorectal cancer in the surrounding lymph nodes., Gastroenterol Res Pract., 2016, 10.1155/2016/2405437 · doi:10.1155/2016/2405437
- Rong, 2016, Analysis of tumor-infiltrating gamma delta T cells in rectal cancer., World J Gastroenterol., 22, 3573, 10.3748/wjg.v22.i13.3573 · doi:10.3748/wjg.v22.i13.3573
- Lee, 2017, Impact Of circulating T helper 1 and 17 cells in the blood on regional lymph node invasion in colorectal cancer., J Cancer., 8, 1249, 10.7150/jca.18230 · doi:10.7150/jca.18230
- Tsang, 2004, Human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1., Clin Cancer Res., 10, 2139, 10.1158/1078-0432.CCR-1011-03 · doi:10.1158/1078-0432.ccr-1011-03
- Andersen, 2006, HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer., J Transl Med., 4, 10.1186/1479-5876-4-38 · doi:10.1186/1479-5876-4-38
- Kameshima, 2011, Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients., Cancer Sci., 102, 1181, 10.1111/j.1349-7006.2011.01918.x · doi:10.1111/j.1349-7006.2011.01918.x
- Uchida, 2004, Ring finger protein 43 as a new target for cancer immunotherapy., Clin Cancer Res., 10, 8577, 10.1158/1078-0432.CCR-04-0104 · doi:10.1158/1078-0432.ccr-04-0104
- Gardini, 2004, Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis., J Surg Oncol., 87, 46, 10.1002/jso.20066 · doi:10.1002/jso.20066
Cited by
The inflammatory pathogenesis of colorectal cancer
Schmitt, M., & Greten, F. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00534-x · Cited by 775
Abedizadeh, R., Majidi, F., Khorasani, H. R., Abedi, H., & Sabour, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10158-3 · Cited by 293
Genetic and epigenetic characteristics of inflammatory bowel disease-associated colorectal cancer
Rajamäki, K., Taira, A., Katainen, R., Välimäki, N., Kuosmanen, A., Plaketti, R.-M., Seppälä, T. T., Ahtiainen, M., Wirta, E.-V., Vartiainen, E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.042 · Cited by 230
Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02676-9 · Cited by 95
“Moreover, the immune landscape of KRASmutated metastatic CRC was designated as ‘immune excluded’ [9, 10], suggesting that immunotherapy will be challenging in this cancer subtype.”
BackgroundBorràs, D. M., Verbandt, S., Ausserhofer, M., Sturm, G., Lim, J., Verge, G. A., Vanmeerbeek, I., Laureano, R. S., Govaerts, J., Sprooten, J., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00605-4 · Cited by 67
“7c), that were either untreated, treated with anti-PD-1 ICB or a combination of anti-PD-1 ICB and celecoxib (NCT03926338) (Fig.”
Influential
Metadata
- Authors
- Picard, E., Verschoor, C. P., Ma, G. W., & Pawelec, G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-03-06
- Volume
- 11
- Pages
- 369-369
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3010538789
- Cited by
- 522
- References
- 188
- FWCI
- 24.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.